Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Reaven’s syndrome X
3. Coronary heart disease (CHD) odds ratio
4. Our "toxic" lifestyle
5. Landscape change in modifiable CVD risk factors
6. An early finding from our lab
7. Visceral obesity and metabolic abnormalities
8. Risk of ischemic heart disease (IHD)
9. Insulin resistance
10. Simple screening tool to find insulin resistance
11. Clinical identification of the metabolic syndrome
12. 2009 harmonized definition of the syndrome
13. Relative risks and the metabolic syndrome
14. Metabolic syndrome: some issues
15. Distinctions of metabolic abnormalities
16. Non-obese individuals metabolic syndrome
17. Waist girth among and metabolic syndrome
18. Abdominal obesity and metabolic syndrome (1)
19. Abdominal obesity and metabolic syndrome (2)
20. Excess liver fat
21. Liver fat and visceral fat: cardiometabolic risk link
22. Liver fat content measurement
23. Sex differences in liver fat content
24. Excess visceral adiposity/liver fat data
25. Visceral adipose tissue and cardiometabolic risk
26. Overall objectives of INSPIRE ME IAA
27. General information: INSPIRE ME IAA
28. Visceral adipose tissue measurement
29. Liver fat measurement (Th12-L1)
30. Cardiometabolic risk
31. Categorization by T2D and tertiles of VAT
32. Triglyceride concentrations in men
33. Triglyceride concentrations in women
34. HDL cholesterol concentrations in men
35. HDL cholesterol concentrations in women
36. Inflammatory factors, visceral adiposity & T2D
37. Liver fat, visceral adiposity & T2D
38. Frequency of prevalent CVD
39. Type 2 diabetes odds ratios
40. Conclusion about excess visceral adiposity/liver
41. Excess visceral/liver fat and high risk obesity
42. Visceral obesity=dysfunctional adipose tissue?
43. Visceral obesity/ectopic fat screening tool
44. Hypertriglyceridemic waist
45. HyperTG waist and CHD risk study
46. HyperTG waist in men
47. HyperTG waist in women
48. Survival of hyperTG waist subgroups in men
49. Survival of hyperTG waist subgroups in women
50. Clinical diagnosis limitations
51. Comparing CHD risk in two cases
52. CHD risk associated with metabolic syndrome
53. Metabolic syndrome: a component of global CMR
54. Visceral adiposity/ectopic fat in risk assessment
55. Management of patients with metabolic syndrome
56. "Turbostatins"
57. The abdominally obese patient
58. More from the EPIC-Norfolk study
59. CHD event rate and physical activity
60. Low cardiorespiratory fitness: CHD risk factor
61. Cardiorespiratory fitness predicts mortality
62. Reshaping lifestyle habits of obese patients
63. The “metabolic syndrome”: summary

Topics Covered

• Reaven’s syndrome X
• Coronary heart disease (CHD) and type 2 diabetes odds ratio
• Our "toxic" lifestyle
• Landscape change in modifiable CVD risk factors
• Risk of ischemic heart disease (IHD)
• Insulin resistance
• The metabolic syndrome: distinctions of metabolic abnormalities, CHD risk, non-obese individuals, waist girth, abdominal obesity and management,- Liver fat and visceral fat: cardiometabolic risk link
• Sex differences in liver fat content
• Overall objectives of INSPIRE ME IAA
• Categorization by T2D and tertiles of VAT
• Triglyceride & HDL cholesterol concentrations in men & women
• Inflammatory factors, liver fat, visceral adiposity & T2D
• Frequency of prevalent CVD
• Visceral obesity/ectopic fat screening tool
• HyperTG waist survival and CHD risk study
• Clinical diagnosis limitations
• "Turbostatins”
• The EPIC-Norfolk study
• CHD event rate and physical activity
• Reshaping lifestyle habits of obese patients

Links

Series:

• Diabetes in Perspective

Categories:

• Biochemistry
• Cell Biology
• Clinical Medicine
• Diseases, Disorders & Treatments
• Metabolism & Nutrition

Therapeutic Areas:

• Cardiovascular & Metabolic

Talk Citation

Després, J.P. (2013, May 22). The metabolic syndrome [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 23, 2019, from https://hstalks.com/bs/2547/.

Publication History

• Published on May 22, 2013

Financial Disclosures

• Prof. Jean Pierre Després, Consultant: Novartis, Thera technologies, Torrent Pharma ; Speaker’s Bureau: Abbot, Astra Zeneca, GSK, Pfizer, Merck.